Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Issues with CAR-T slot allocation in myeloma & the promise of locally manufactured products

Heinz Ludwig • 27 Sep 2023
IMS 2023
Multiple Myeloma CAR-T

In this video, Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Vienna, Austria, discusses issues regarding CAR-T slot allocation in multiple myeloma, and further comments on how academic and locally manufactured products may be used to overcome this challenge. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Heinz Ludwig

2:50
Immunotherapy highlights at IMS 2023: bispecific antibodies, CAR-T cells & unanswered questions
Heinz Ludwig • 27 Sep 2023
3:49
Advances in technologies used to assess immune function in myeloma
Heinz Ludwig • 27 Sep 2023
2:59
Managing COVID-19 risks and exposures in patients with myeloma
Heinz Ludwig • 12 May 2023
1:33
Why are elderly patients underrepresented in myeloma clinical trials?
Heinz Ludwig • 12 May 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals